AR101440A1 - MÚLTIPLES ARNi DIRIGIDOS PARA EL TRATAMIENTO DEL CÁNCER - Google Patents

MÚLTIPLES ARNi DIRIGIDOS PARA EL TRATAMIENTO DEL CÁNCER

Info

Publication number
AR101440A1
AR101440A1 ARP150101261A ARP150101261A AR101440A1 AR 101440 A1 AR101440 A1 AR 101440A1 AR P150101261 A ARP150101261 A AR P150101261A AR P150101261 A ARP150101261 A AR P150101261A AR 101440 A1 AR101440 A1 AR 101440A1
Authority
AR
Argentina
Prior art keywords
expression
gene
cleavage
rna molecule
reduces
Prior art date
Application number
ARP150101261A
Other languages
English (en)
Inventor
Lonard David
W Omalley Bert
Nemunaitis John
Rao Donald
Original Assignee
Baylor College Medicine
Strike Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College Medicine, Strike Bio Inc filed Critical Baylor College Medicine
Publication of AR101440A1 publication Critical patent/AR101440A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/51—Physical structure in polymeric form, e.g. multimers, concatemers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Reivindicación 1: Una composición de ARNhp bifuncional capaz de reducir la expresión de tres o más genes, caracterizada porque comprende: una primera molécula de ARN bifuncional que reduce la expresión de un primer gen blanco; una segunda molécula de ARN bifuncional que reduce la expresión de un segundo gen blanco; y una tercera molécula de ARN bifuncional que reduce la expresión de un tercer gen blanco, en donde cada una de las moléculas de ARN bifuncional pueden activar un complejo de silenciamiento inducido por ARN dependiente de clivaje e independiente de clivaje para reducir el nivel de expresión de dichos primer, segundo y tercer genes blanco. Reivindicación 6: Los ARNhp bifuncionales de la reivindicación 1, caracterizados porque por lo menos la primera, la segunda o la tercera molécula de ARN bifuncional se selecciona entre las SEQ ID Nº 5 - 22, las SEQ ID Nº 23 - 32, las SEQ ID Nº 33 - 34, las SEQ ID Nº 36 - 37, las SEQ ID Nº 38 - 39 o las SEQ ID Nº 44 - 45. Reivindicación 9: Un vector de expresión, caracterizado porque comprende: un promotor; y un inserto de ácido nucleico ligado operativamente al promotor, en donde el inserto comprende: una primera molécula de ARN bifuncional que reduce la expresión de un primer gen blanco; una segunda molécula de ARN bifuncional que reduce la expresión de un segundo gen blanco; y una tercera molécula de ARN bifuncional que reduce la expresión de un tercer gen blanco, en donde la molécula de ARN bifuncional puede activar un complejo de silenciamiento inducido por ARN dependiente de clivaje e independiente de clivaje para reducir el nivel de expresión del primer, segundo y tercer genes blanco, en donde dichos uno o más ARNhp comprenden una molécula de ARN bifuncional que activa un complejo de silenciamiento inducido por ARN dependiente de clivaje e independiente de clivaje para reducir el nivel de expresión del primer, segundo y tercer genes blanco. Reivindicación 15: Un sistema de administración terapéutico, caracterizado porque comprende: un vehículo del agente terapéutico; y un vector de expresión que comprende un promotor y un inserto de ácido nucleico ligado operativamente al promotor, donde el inserto de ácido nucleico codifica: una primera molécula de ARN bifuncional que reduce la expresión de un primer gen blanco; una segunda molécula de ARN bifuncional que reduce la expresión de un segundo gen blanco; y una tercera molécula de ARN bifuncional que reduce la expresión de un tercer gen blanco, en donde cada una de las moléculas de ARN bifuncional puede activar un complejo de silenciamiento inducido por ARN dependiente de clivaje e independiente de clivaje para reducir el nivel de expresión de dichos primer, segundo y tercer genes blanco. Reivindicación 27: Un método para suprimir un crecimiento de células tumorales en un sujeto humano, caracterizado porque comprende los pasos de: identificar al sujeto humano que necesita dicha supresión del crecimiento de células tumorales; y administrar un vector de expresión en un complejo transportador del agente terapéutico al sujeto humano en una cantidad suficiente como para suprimir el crecimiento de células tumorales, en donde el vector de expresión comprende un inserto de ácido nucleico ligado operativamente al promotor, en donde el inserto comprende: una primera molécula de ARN bifuncional que reduce la expresión de un gen KRAS mutado; una segunda molécula de ARN bifuncional que reduce la expresión de un gen SRC-3; y una tercera molécula de ARN bifuncional que reduce la expresión de un gen del receptor del factor de crecimiento epidérmico (EGFR), en donde la molécula de ARN bifuncional puede activar un complejo de silenciamiento inducido por ARN dependiente de clivaje e independiente de clivaje para reducir el nivel de expresión de los genes KRAS, SRC-3 y EGFR mutados, y en donde la inhibición da como resultado la apoptosis, el arresto de la proliferación o una menor capacidad de invasión de las células tumorales. Reivindicación 36: Un método para evaluar un fármaco candidato considerado de utilidad en el tratamiento de un cáncer, caracterizado porque dicho método comprende: (a) medir uno o más entre: el nivel de expresión de por lo menos un gen KRAS de tipo salvaje y uno o más genes KRAS mutados, y dos o más genes blanco en las células o los tejidos del cáncer; el nivel de expresión de un gen candidato o de un grupo de genes candidato en un entorno celular con expresión disminuida de uno o más genes KRAS mutados, y de dos o más genes blanco en las células o los tejidos del cáncer; el efecto de un fármaco candidato sobre el fenotipo de dichas células compuesta por una expresión disminuida de uno o más genes KRAS mutados y los dos o más genes blanco en las células o los tejidos del cáncer; (b) administrar un fármaco candidato a un primer subconjunto de dichas células o tejidos de cáncer, y un placebo a un segundo subconjunto de dichas células o tejidos de cáncer; (c) repetir el paso (a) después de la administración de la fármaco candidato o del placebo; y (d) determinar si el fármaco candidato es efectivo en la producción de un determinado fenotipo en un entorno celular con expresión reducida del gen KRAS mutado y los dos o más genes blanco en comparación con un entorno celular que expresa un gen KRAS normal de manera estadísticamente significativa en comparación con cualquier reducción que tuviera lugar en el segundo subconjunto de células o tejidos de cáncer de pulmón, en donde una reducción estadísticamente significativa indica que el fármaco candidato es de utilidad en el tratamiento de cáncer. Reivindicación 39: Un método para suprimir el crecimiento de células tumorales en un sujeto humano, caracterizado porque comprende los pasos de: obtener una muestra de células tumorales del sujeto humano; identificar uno o más genes blanco en el sujeto humano que necesita dicha supresión para impedir el crecimiento de células tumorales; construir un vector de expresión que comprenda un inserto que expresa dos o más segmentos de ácidos nucleicos de ARNi dirigidos específicamente contra el o los genes identificados en la muestra de células tumorales; en donde dicho inserto comprende: un primer y un segundo ácido nucleico de ARNi que reduce la expresión del mismo gen blanco o de genes blanco diferentes identificados en las células tumorales; administrar el vector de expresión en un complejo transportador del agente terapéutico al sujeto humano en una cantidad suficiente como para expresar dichos dos o más segmentos de ácidos nucleicos de ARNi; y determinar si el o los genes fueron noqueados por el vector de expresión en las células tumorales de interés, en donde la inhibición da como resultado la apoptosis, el arresto de la proliferación o una menor capacidad de invasión de las células tumorales.
ARP150101261A 2014-04-25 2015-04-27 MÚLTIPLES ARNi DIRIGIDOS PARA EL TRATAMIENTO DEL CÁNCER AR101440A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461984614P 2014-04-25 2014-04-25

Publications (1)

Publication Number Publication Date
AR101440A1 true AR101440A1 (es) 2016-12-21

Family

ID=57860013

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150101261A AR101440A1 (es) 2014-04-25 2015-04-27 MÚLTIPLES ARNi DIRIGIDOS PARA EL TRATAMIENTO DEL CÁNCER

Country Status (3)

Country Link
EP (1) EP3134528A4 (es)
CN (1) CN106661576A (es)
AR (1) AR101440A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110283825B (zh) * 2019-07-30 2023-05-23 大连医科大学 可敲低SRC-1基因表达的siRNA及其应用
CN112980840A (zh) * 2019-12-17 2021-06-18 南京大学 用于癌症治疗的多靶向siRNA
CN112011573A (zh) * 2020-07-21 2020-12-01 山西医科大学 一种转染小鼠原代神经元的慢病毒载体及构建方法
CN111996193B (zh) 2020-09-11 2024-02-20 北京键凯科技股份有限公司 一种有效抑制表皮生长因子受体表达的siRNA序列
CN116600818A (zh) 2020-10-28 2023-08-15 贝勒医学院 靶向免疫细胞中的src-3作为治疗癌症的免疫调节治疗剂
CN117327703B (zh) * 2023-11-22 2024-04-23 青岛大学附属医院 一种靶向平滑肌细胞的Agrin-shRNA及其在制备抗动脉粥样硬化的药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8906874B2 (en) * 2006-11-09 2014-12-09 Gradalis, Inc. Bi-functional shRNA targeting Stathmin 1 and uses thereof
SG188160A1 (en) * 2009-12-23 2013-03-28 Gradalis Inc Furin-knockdown and gm-csf-augmented (fang) cancer vaccine
US20130064881A1 (en) * 2011-09-08 2013-03-14 Gradalis, Inc. Compositions and methods for treating prostate cancer
WO2013148824A1 (en) * 2012-03-28 2013-10-03 Gradalis, Inc. METHODS AND COMPOSITIONS TO TREAT CANCER USING BIFUNCTIONAL SRC-3 shRNA
US20130259926A1 (en) * 2012-03-28 2013-10-03 Gradalis, Inc. BI-FUNCTIONAL shRNA TARGETING MESOTHELIN AND USES THEREOF
WO2013170071A1 (en) * 2012-05-09 2013-11-14 Gradalis, Inc. Bi-functional short-hairpin rna (bi-shrna) specific for single-nucleotide kras mutations

Also Published As

Publication number Publication date
CN106661576A (zh) 2017-05-10
EP3134528A1 (en) 2017-03-01
EP3134528A4 (en) 2017-12-06

Similar Documents

Publication Publication Date Title
AR101440A1 (es) MÚLTIPLES ARNi DIRIGIDOS PARA EL TRATAMIENTO DEL CÁNCER
Ahn et al. Extrinsic phagocyte-dependent STING signaling dictates the immunogenicity of dying cells
DeVorkin et al. Autophagy regulation of metabolism is required for CD8+ T cell anti-tumor immunity
Di Micco et al. Cellular senescence in ageing: from mechanisms to therapeutic opportunities
Jin et al. Circular RNA hsa_circ_0000523 regulates the proliferation and apoptosis of colorectal cancer cells as miRNA sponge
Sansone et al. Packaging and transfer of mitochondrial DNA via exosomes regulate escape from dormancy in hormonal therapy-resistant breast cancer
Jia et al. Long non-coding RNA H19 regulates glioma angiogenesis and the biological behavior of glioma-associated endothelial cells by inhibiting microRNA-29a
Floyd et al. Novel anti-apoptotic microRNAs 582-5p and 363 promote human glioblastoma stem cell survival via direct inhibition of caspase 3, caspase 9, and Bim
Bednarek et al. Telomerase is essential for zebrafish heart regeneration
Shi et al. miR-145 inhibits migration and invasion of glioma stem cells by targeting ABCG2
Liu et al. Long noncoding RNA FAM201A involves in radioresistance of non-small-cell lung cancer by enhancing EGFR expression via miR-370.
Liu et al. SET-mediated NDRG1 inhibition is involved in acquisition of epithelial-to-mesenchymal transition phenotype and cisplatin resistance in human lung cancer cell
BR112015000660A2 (pt) uso de uma terapia de primeira linha e uma terapia de segunda linha para tratamento de um paciente possuindo uma doença, desordem ou condição associada com uma expressão elevada de um antígeno de tumor, e de uma composição para reduzir ou evitar um efeito adverso associado com a administração de uma célula geneticamente modificada para expressar um car.
Xu et al. Oxidative stress preferentially induces a subtype of micronuclei and mediates the genomic instability caused by p53 dysfunction
Liu et al. MicroRNA-15a carried by mesenchymal stem cell-derived extracellular vesicles inhibits the immune evasion of colorectal cancer cells by regulating the KDM4B/HOXC4/PD-L1 axis
Gao et al. LncRNA PCAT1 activates SOX2 and suppresses radioimmune responses via regulating cGAS/STING signalling in non‐small cell lung cancer
Zhao et al. Drosha-independent miR-6778–5p strengthens gastric cancer stem cell stemness via regulation of cytosolic one-carbon folate metabolism
Mao et al. Optimization of BCG therapy targeting neutrophil extracellular traps, autophagy, and miRNAs in bladder cancer: implications for personalized medicine
Liu et al. Downregulation of MicroRNA‐206 Alleviates the Sublethal Oxidative Stress‐Induced Premature Senescence and Dysfunction in Mesenchymal Stem Cells via Targeting Alpl
Nagahisa et al. Characteristics of skeletal muscle fibers of SOD1 knockout mice
Li et al. The roles of epigallocatechin gallate in the tumor microenvironment, metabolic reprogramming, and immunotherapy
Al-Hawary et al. Highlighting the role of long non-coding RNA (LncRNA) in multiple myeloma (MM) pathogenesis and response to therapy
CN115461461A (zh) 用于促进免疫原性细胞死亡的miRNA-193a
Wilczyński et al. “DEPHENCE” system—a novel regimen of therapy that is urgently needed in the high-grade serous ovarian cancer—a focus on anti-cancer stem cell and anti-tumor microenvironment targeted therapies
Matsubara et al. Depletion of RUVBL2 in human cells confers moderate sensitivity to anticancer agents

Legal Events

Date Code Title Description
FB Suspension of granting procedure